A Vaccine Study for High Risk Cancers

Inclusion criteria

for Screening Phase: Patient 1 to 70 years of age with neuroblastoma, rhabdomyosarcoma, or osteogenic sarcoma, who have one or more of the following high risk features: * Neuroblastoma: * Stage IV disease * Stage III disease with n-myc amplification * Osteogenic sarcoma: * Presence of metastases * Elevated alkaline phosphatase or LDH at diagnosis * Primary tumor affecting the axial skeleton * Poor histopathological response after completion of pre-surgical chemotherapy (≥10% viable tumor) * Rhabdomyosarcoma: * Stage IV disease * Alveolar histology * Positive tumor margins, with lymph node positivity Inclusion Criteria for Vaccine Phase: * Patient meets all screening criteria and tumor is positive for NY-ESO-1, MAGE- A1, or MAGE-A3 by immunohistochemistry or RT-PCR. * Patients who are between 3 months and 2 years following the completion of therapy, and have achieved at least a very good partial response to primary therapy. * No chemotherapy is planned for one month following the last vaccination. * Bilirubin \<2 mg/dL, and SGOT/SGPT \<2.5 x normal * Creatinine clearance \> 50ml/min as estimated by patient's serum creatinine, weight, and age * Room air pulse oximetry \>94% * Patient is not pregnant * Male and female sexually active patients of reproductive who wish to participate must agree to use acceptable contraception * Patient is not moribund and has a projected life expectancy \>6 months * Lansky performance scale \> 70, ECOG \< 2 (Appendix I) * Potential subjects will be tested for HIV 1 and 2 antibodies, HTLV 1/2 antibodies, and for HIV 1, hepatitis C and hepatitis B virus by NAT testing. - -Subjects testing positive for any of these pathogens will be ineligible for vaccine. * White blood cells ≥ 2.5 K/µL, Hemoglobin ≥ 8 g/dL, Hematocrit \> 25%, and Platelets ≥ 70 K/µL * Patient does not have central nervous system involvement. * Patient does not a have a history of autoimmune disease, specifically inflammatory bowel disease, systemic lupus erythematosis, or rheumatoid arthritis * Patient is not receiving concurrent systemic steroid therapy * Patient does not have a known systemic hypersensitivity to imiquimod or any vaccine component